

Belgium: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2017 (n/100,000 person years)

Belgium: Females 2017	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRi
C00 Lip	9	-	-	-	-	-	-	-	-	-	-	-	0.3	0.3	0.6	-	-	1.1	1.4	0.2	0.1	0.1	0.01
C01 Base of tongue	51	-	-	-	-	-	-	-	-	-	0.8	0.7	2.1	4.0	3.2	2.4	1.9	1.1	0.5	0.9	0.7	0.5	0.07
C02 Tongue	83	-	-	-	-	-	0.3	0.3	0.5	0.8	0.8	1.7	3.6	3.2	4.1	2.7	1.9	5.8	2.8	1.4	1.1	0.8	0.09
C03 Gum	47	-	-	-	-	-	-	-	-	-	0.3	0.5	0.8	0.6	2.5	3.5	2.8	3.7	4.3	0.8	0.5	0.3	0.04
C04 Floor of mouth	54	-	-	-	-	-	-	-	-	-	1.0	1.2	2.1	2.6	3.2	2.7	2.4	1.6	1.4	0.9	0.7	0.5	0.06
C05 Palate	36	-	-	-	-	0.3	0.3	0.3	-	-	0.3	1.5	1.3	1.1	1.0	2.0	0.9	1.1	2.4	0.6	0.5	0.3	0.04
C06 Mouth, NOS	23	-	-	-	-	-	-	-	-	-	-	-	0.5	0.9	-	1.6	2.4	1.6	2.8	0.4	0.2	0.1	0.01
C07 Parotid gland	43	-	-	-	-	-	-	-	0.5	0.5	0.5	0.5	0.8	0.9	0.3	2.4	3.8	3.2	3.8	0.7	0.5	0.3	0.03
C08 Salivary glands, NOS	16	-	-	-	-	0.3	0.3	0.3	0.5	0.3	-	-	0.5	0.3	1.3	-	0.5	0.5	0.5	0.3	0.2	0.2	0.02
C09 Tonsil	80	-	-	-	-	-	-	-	-	0.3	1.8	1.5	3.1	4.3	5.1	4.3	4.2	0.5	0.9	1.4	1.1	0.8	0.10
C10 Oropharynx	48	-	-	-	-	-	-	-	-	-	0.5	2.2	1.8	1.7	2.9	3.5	0.9	1.1	0.9	0.8	0.6	0.5	0.06
C11 Nasopharynx	13	-	-	-	-	0.3	0.3	-	-	-	-	0.5	0.3	0.9	0.3	0.8	-	0.5	0.5	0.2	0.2	0.1	0.02
C12 Pyriform sinus	37	-	-	-	-	-	-	-	-	-	-	1.7	2.8	1.7	1.0	1.6	2.4	0.5	-	0.6	0.5	0.4	0.04
C13 Hypopharynx	21	-	-	-	-	-	-	-	0.3	-	-	0.2	0.3	1.1	1.6	1.2	1.4	1.6	-	0.4	0.3	0.2	0.02
C14 Lip, oral cavity and pharynx, NOS	3	-	-	-	-	-	-	-	-	-	-	0.2	-	0.3	-	-	-	-	0.5	0.1	0.0	0.0	0.00
C15 Oesophagus	261	-	-	-	-	-	-	0.3	-	0.5	1.3	3.0	6.4	8.9	13.0	18.5	15.1	15.3	17.0	4.5	2.9	2.0	0.26
C16 Stomach	503	-	-	-	-	-	-	0.8	1.3	3.3	5.2	5.2	13.2	12.6	17.5	28.3	27.3	44.4	36.9	8.7	5.4	3.7	0.44
C17 Small intestine	140	-	-	-	-	0.3	0.3	-	0.8	1.4	2.1	3.0	3.1	4.3	5.4	10.6	6.6	5.8	6.6	2.4	1.7	1.2	0.16
C18 Colon	2,722	-	-	0.3	2.3	2.4	2.7	5.5	7.0	6.3	18.8	22.0	48.0	70.6	106.6	148.1	170.2	242.9	237.1	47.3	28.0	19.0	2.18
C19 Rectosigmoid junction	66	-	-	-	-	-	-	-	-	0.3	-	0.2	1.0	1.7	3.8	2.7	5.2	5.8	6.2	1.1	0.6	0.4	0.05
C20 Rectum	844	-	-	-	-	0.3	0.8	0.8	3.2	4.4	5.7	14.6	21.9	30.7	35.3	46.7	40.1	58.2	52.5	14.7	9.7	6.7	0.82
C21 Anus and anal canal	106	-	-	-	-	-	-	0.3	0.3	1.1	1.8	2.7	3.6	3.2	4.5	5.9	3.3	4.8	5.7	1.8	1.3	1.0	0.12
C22 Liver and intrahepatic bile ducts	263	0.7	0.3	-	-	-	-	0.3	0.5	0.8	2.1	3.2	4.4	8.9	12.1	14.5	17.9	23.8	12.8	4.6	2.9	2.0	0.24
C23 Gallbladder	60	-	-	-	-	-	-	-	0.3	0.3	0.5	0.7	0.8	2.0	2.9	3.1	4.7	3.7	4.3	1.0	0.7	0.4	0.05
C24 Biliary tract, NOS	142	-	-	-	-	0.3	-	-	0.3	-	1.3	1.2	1.5	3.7	5.7	5.9	9.9	11.6	16.6	2.5	1.4	0.9	0.10
C25 Pancreas	884	-	-	-	0.3	0.3	0.3	0.8	1.1	3.0	4.9	9.2	17.5	24.4	35.0	60.1	67.4	66.1	58.2	15.4	9.5	6.3	0.78
C26 Other ill-defined digestive organs	10	-	-	-	-	-	-	-	0.3	-	0.3	-	0.3	0.6	0.6	-	0.5	0.5	0.5	0.2	0.1	0.1	0.01
C30 Nasal cavity and middle ear	26	-	-	-	-	-	-	-	-	-	0.3	0.2	0.5	1.7	1.0	1.6	0.9	0.5	2.8	0.5	0.3	0.2	0.03
C31 Accessory sinuses	13	-	-	-	-	-	0.5	-	-	-	-	0.5	0.3	1.7	0.3	-	-	0.5	-	0.2	0.2	0.2	0.02
C32 Larynx	95	-	-	-	-	-	-	-	0.3	0.3	0.8	0.7	4.4	6.9	3.8	5.1	3.8	3.2	3.3	1.7	1.2	0.9	0.11
C33 Trachea	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.4	-	-	-	0.0	0.0	0.0	0.00
C34 Bronchus and lung	2,873	-	-	0.7	-	-	0.3	2.2	4.3	8.8	20.4	50.2	88.2	138.2	170.9	185.0	150.8	120.6	71.9	49.9	35.6	25.1	3.29
C37 Thymus	37	-	-	-	-	-	-	-	0.5	1.1	0.5	0.5	1.3	2.0	1.0	1.6	1.9	2.1	-	0.6	0.5	0.4	0.04
C38 Heart, mediastinum and pleura	11	-	-	-	0.3	-	-	-	-	-	-	0.5	-	0.3	1.0	0.4	-	1.1	0.5	0.2	0.1	0.1	0.01
C39 Respiratory system and intrathoracic organs, NOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C40 Bone and articular cartilage of limbs	27	-	-	0.7	0.6	-	0.3	-	-	0.5	0.3	0.7	0.8	0.6	1.0	1.6	1.4	0.5	-	0.5	0.4	0.4	0.03
C41 Bone and articular cartilage, NOS	25	0.3	0.3	0.7	0.3	0.6	0.5	0.3	0.3	0.5	-	0.2	0.8	0.9	0.6	0.4	0.5	-	0.5	0.4	0.4	0.4	0.03
C43 Malignant melanoma of skin	1,916	0.3	-	0.7	3.2	6.3	18.0	24.8	29.9	42.9	52.3	55.7	46.4	45.0	55.1	62.1	54.2	65.6	58.7	33.3	27.8	21.8	2.19
C44 Malignant neoplasms of skin	3,292	-	-	0.3	-	0.6	0.5	2.2	5.1	3.6	14.4	25.0	36.1	47.9	78.0	154.3	238.0	323.3	487.0	57.2	28.8	18.1	1.82

Belgium: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2017 (n/100,000 person years)

Belgium: Females 2017	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRI
C45 Mesothelioma	61	-	-	-	-	-	-	-	-	0.3	-	1.2	0.5	1.4	1.6	4.7	4.7	6.3	4.3	1.1	0.6	0.4	0.05
C46 Kaposi's sarcoma	9	-	-	-	-	-	-	-	0.3	-	0.3	-	0.5	0.3	-	-	-	1.1	0.9	0.2	0.1	0.1	0.01
C47,C49 Soft tissues	171	1.6	0.3	-	0.3	0.3	0.8	0.8	0.8	2.2	3.4	2.5	3.6	4.3	2.5	7.5	9.0	10.6	13.3	3.0	2.1	1.7	0.15
C48 Retroperitoneum and peritoneum	68	0.7	-	-	-	0.3	0.3	-	0.5	-	0.8	0.7	1.0	2.6	1.9	3.5	5.7	7.4	0.9	1.2	0.8	0.6	0.06
C50 Breast	10,627	-	-	-	0.3	3.3	12.5	32.8	81.7	166.6	241.3	300.8	307.0	379.1	424.8	429.7	391.2	436.0	375.8	184.7	142.0	104.4	11.22
C51 Vulva	219	-	-	-	-	-	0.3	0.8	1.1	1.1	2.6	3.2	6.2	3.7	7.3	9.0	8.5	20.6	20.8	3.8	2.3	1.6	0.18
C52 Vagina	46	-	-	-	-	-	-	-	-	0.3	0.8	0.5	1.3	2.0	2.2	2.4	2.8	1.6	2.8	0.8	0.5	0.4	0.05
C53 Cervix uteri	622	-	-	-	-	0.9	4.1	10.2	16.2	18.4	16.8	20.0	20.4	17.2	12.1	12.2	15.1	12.2	14.7	10.8	9.6	7.5	0.74
C54 Corpus uteri	1,394	-	-	-	-	-	0.5	0.6	1.3	3.8	7.2	19.0	33.3	48.2	71.3	97.8	90.0	90.0	63.9	24.2	15.8	10.8	1.41
C55 Uterus	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.4	-	-	1.9	0.1	0.0	0.0	0.00
C56 Ovary	784	-	0.3	-	0.6	0.6	1.6	1.7	4.0	4.1	11.1	15.6	18.1	29.8	29.6	46.7	45.2	39.7	35.0	13.6	9.6	6.9	0.82
C57 Female genital organs, NOS	94	-	-	-	-	-	0.3	-	-	0.3	1.0	2.0	2.3	3.7	6.0	4.7	5.7	4.2	3.3	1.6	1.1	0.8	0.10
C58 Placenta	7	-	-	-	-	-	0.3	0.8	-	0.3	0.5	-	-	-	-	-	-	-	-	0.1	0.1	0.1	0.01
C64 Kidney	647	2.0	1.2	-	-	0.6	0.3	0.6	2.7	3.3	5.9	9.6	11.6	24.1	31.8	41.6	37.7	35.5	31.2	11.2	7.7	5.6	0.67
C65 Renal pelvis	80	-	-	-	-	-	-	-	-	-	0.5	0.2	0.5	1.1	1.9	3.9	9.0	7.4	10.4	1.4	0.7	0.4	0.04
C66 Ureter	54	-	-	-	-	-	-	-	-	-	0.3	0.2	0.8	2.6	1.6	2.4	5.2	4.2	4.7	0.9	0.5	0.4	0.04
C67 Bladder	462	0.3	-	-	-	-	-	-	0.8	0.8	1.5	3.5	8.8	9.5	15.0	22.4	34.9	41.3	53.0	8.0	4.4	2.8	0.31
C68 Urinary organs, NOS	10	-	-	-	-	-	-	-	-	-	-	-	-	0.6	0.6	1.6	-	0.5	0.5	0.2	0.1	0.1	0.01
C69 Eye and adnexa	71	1.6	-	-	-	-	-	-	0.3	0.5	1.0	2.0	1.3	4.0	2.2	3.1	1.9	4.2	2.4	1.2	1.0	0.8	0.08
C70 Meninges	11	-	-	-	-	-	-	0.3	-	-	0.3	0.2	-	0.9	-	0.8	0.5	-	0.9	0.2	0.1	0.1	0.01
C71 Brain	316	1.3	1.8	1.3	1.6	0.6	1.1	1.7	3.0	4.4	3.9	4.2	7.7	12.6	13.4	14.1	15.6	12.2	8.5	5.5	4.3	3.5	0.36
C72 Spinal cord, cranial nerves and CNS, NOS	23	1.0	0.3	-	0.6	0.3	-	-	0.3	0.3	0.5	1.0	0.3	1.4	0.3	-	-	0.5	-	0.4	0.4	0.4	0.03
C73 Thyroid gland	751	-	-	0.3	1.6	5.1	12.0	15.7	20.5	20.6	21.1	17.3	19.1	20.4	18.8	19.6	19.3	8.5	6.2	13.1	12.0	9.9	0.96
C74 Adrenal gland	39	0.7	0.3	-	-	-	0.3	0.6	0.3	0.5	0.8	1.0	1.8	0.9	1.6	2.0	0.5	0.5	0.5	0.7	0.6	0.5	0.05
C75 Endocrine glands, NOS	30	-	0.3	-	0.3	-	0.3	1.4	0.5	0.3	0.5	1.5	0.3	0.6	1.0	0.8	1.4	-	-	0.5	0.5	0.4	0.04
C81 Hodgkin lymphoma	136	-	0.3	2.3	6.2	4.8	3.0	3.0	1.3	3.0	1.3	2.2	1.5	1.1	2.9	3.5	1.9	3.2	1.4	2.4	2.4	2.4	0.18
C82-C86 Non-Hodgkin-lymphoma	920	-	1.2	-	1.9	2.7	2.4	2.2	4.3	7.1	7.2	13.6	20.9	26.4	36.6	49.5	56.6	61.9	51.1	16.0	10.8	7.8	0.88
C88 Malignant immunoproliferative diseases	168	-	-	-	-	-	-	0.8	0.3	0.3	2.8	2.0	3.4	5.7	4.5	11.4	10.8	12.7	9.9	2.9	1.9	1.3	0.16
C90 Multiple myeloma	417	-	-	-	-	-	-	-	1.1	1.9	1.5	4.9	8.3	8.6	21.0	29.8	30.2	33.9	22.7	7.2	4.5	3.0	0.39
C91 Lymphoid leukaemia	407	5.5	2.8	1.0	1.0	0.6	0.5	0.3	1.3	1.1	3.6	6.7	10.6	9.8	17.5	20.4	28.3	19.6	19.4	7.1	5.2	4.1	0.41
C92 Myeloid leukaemia	338	0.3	1.2	-	1.9	1.8	1.4	1.1	2.7	4.9	5.9	4.7	5.7	8.6	14.0	18.1	20.7	12.2	15.6	5.9	4.4	3.4	0.36
C93 Monocytic leukaemia	56	-	-	0.3	-	0.3	-	-	-	0.5	0.5	0.7	-	0.9	2.2	2.4	1.9	7.4	6.2	1.0	0.5	0.4	0.04
C94-C95 Leukaemia other	12	0.7	-	-	-	-	-	-	-	-	-	-	0.5	1.1	-	0.4	-	0.5	0.9	0.2	0.2	0.2	0.01
C96 Lymphoid, haematopoietic and related tissue, NOS	7	0.3	-	-	-	-	-	-	-	-	-	-	0.3	-	0.3	1.2	-	-	0.5	0.1	0.1	0.1	0.01
C76 Other and ill-defined sites	7	0.3	-	-	-	-	-	-	-	-	-	-	-	-	0.3	0.4	0.5	0.5	0.9	0.1	0.1	0.1	0.01
C80 Unknown primary site	341	-	-	-	-	-	-	0.3	1.1	1.4	2.3	4.2	7.0	8.3	11.8	15.3	20.7	31.7	32.7	5.9	3.5	2.3	0.26
MPN Myeloproliferative neoplasms	383	0.3	-	-	1.0	0.6	0.3	2.2	1.3	3.8	3.6	2.7	6.4	12.0	13.4	22.4	24.5	25.4	27.4	6.7	4.3	3.1	0.35
MDS Myelodysplastic syndromes	343	-	-	0.7	-	0.3	0.3	-	0.5	0.5	1.3	1.5	4.4	8.6	9.2	18.9	26.4	39.7	32.7	6.0	3.2	2.1	0.23
Total	35,017	17.9	10.8	9.1	24.7	35.0	67.8	117.0	205.7	334.0	490.9	661.6	835.9	1,102.7	1,363.3	1,710.0	1,771.3	2,017.7	1,979.1	608.6	424.9	306.8	29.48
Total excl. non-melanoma	31,725	17.9	10.8	8.8	24.7	34.4	67.2	114.8	200.6	330.4	476.5	636.6	799.8	1,054.8	1,285.3	1,555.6	1,533.3	1,694.4	1,492.1	551.3	396.1	288.7	28.17
Total excl. non-melanoma and MDS, MPN	30,999	17.6	10.8	8.2	23.7	33.5	66.7	112.6	198.7	326.0	471.6	632.4	788.9	1,034.2	1,262.7	1,514.4	1,482.4	1,629.3	1,432.0	538.7	388.5	283.5	27.75

CR: crude (all ages) incidence rate (n/100,000 person years)

ESR and WSR: age standardised incidence rate, using the European or World Standard Population (n/100,000 person years)

CRI: Cumulative Risk (0-74 years)